{
  "ptid_time": "023_S_0126_2011-02-23",
  "img_path": "/data/qiuhui/data/adni/images/023_S_0126/2011-02-23/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 52,552 mm³, 42.2% above the reference mean. With a Z-score of 1.14 (87.3th percentile), this represents mild enlargement; hippocampal volume measures 3,788 mm³, 41.7% below the reference mean. With a Z-score of -3.34 (0.0th percentile), this represents profound atrophy; whole brain volume measures 812,189 mm³, 12.5% below the reference mean. With a Z-score of -1.50 (6.7th percentile), this represents mild atrophy; entorhinal cortex volume measures 1,615 mm³, 53.4% below the reference mean. With a Z-score of -2.88 (0.2th percentile), this represents significant atrophy; fusiform gyrus volume measures 11,161 mm³, 30.7% below the reference mean. With a Z-score of -2.31 (1.0th percentile), this represents significant atrophy; middle temporal gyrus volume measures 12,384 mm³, 31.3% below the reference mean. With a Z-score of -2.79 (0.3th percentile), this represents significant atrophy. ",
  "text_data": "Age is 82.5 years. Gender is Female. Education: 14 years. Handedness: Right. Race: White. Medical history: Allergies or Drug Sensitivities. MMSE: 24.0. MoCA: 20.0. Logical Memory: 0.0. APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.36 SUVR (significant elevated); Amyloid beta: 663.70 pg/mL (normal ); Total tau: 257.00 pg/mL (normal ); Phosphorylated tau: 21.41 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows profound hippocampal atrophy (Z-score -3.34) and significant atrophy in the entorhinal cortex, fusiform gyrus, and middle temporal gyrus—all key regions affected in Alzheimer’s disease (AD). Despite normal CSF biomarkers (Aβ, T-tau, P-tau), the elevated AV45 (amyloid PET) suggests amyloid pathology. The cognitive scores (MMSE 24, MoCA 20) indicate mild impairment, consistent with early dementia.  \n\n**Diagnosis:** **Dementia (likely Alzheimer’s disease)**  \n**Confidence:** **High** (due to severe atrophy in AD-vulnerable regions, elevated amyloid PET, and cognitive decline, even with normal CSF biomarkers, which can occur in late-onset AD).",
  "timestamp": "2025-07-26T02:37:20.224677"
}